GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akers Biosciences Inc (NAS:AKER) » Definitions » ROA %

Akers Biosciences (Akers Biosciences) ROA % : -43.42% (As of Dec. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Akers Biosciences ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Akers Biosciences's annualized Net Income for the quarter that ended in Dec. 2020 was $-13.15 Mil. Akers Biosciences's average Total Assets over the quarter that ended in Dec. 2020 was $30.28 Mil. Therefore, Akers Biosciences's annualized ROA % for the quarter that ended in Dec. 2020 was -43.42%.

The historical rank and industry rank for Akers Biosciences's ROA % or its related term are showing as below:

AKER's ROA % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -1.84
* Ranked among companies with meaningful ROA % only.

Akers Biosciences ROA % Historical Data

The historical data trend for Akers Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akers Biosciences ROA % Chart

Akers Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.47 -102.14 -126.56 -41.60 -73.67

Akers Biosciences Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.56 -141.51 -104.40 -134.46 -43.42

Competitive Comparison of Akers Biosciences's ROA %

For the Medical Instruments & Supplies subindustry, Akers Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akers Biosciences's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akers Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Akers Biosciences's ROA % falls into.



Akers Biosciences ROA % Calculation

Akers Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2020 is calculated as:

ROA %=Net Income (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=-17.581/( (10.885+36.843)/ 2 )
=-17.581/23.864
=-73.67 %

Akers Biosciences's annualized ROA % for the quarter that ended in Dec. 2020 is calculated as:

ROA %=Net Income (Q: Dec. 2020 )/( (Total Assets (Q: Sep. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=-13.148/( (23.725+36.843)/ 2 )
=-13.148/30.284
=-43.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2020) net income data. ROA % is displayed in the 30-year financial page.


Akers Biosciences  (NAS:AKER) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2020 )
=Net Income/Total Assets
=-13.148/30.284
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-13.148 / 0)*(0 / 30.284)
=Net Margin %*Asset Turnover
=N/A %*0
=-43.42 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) net income data. The Revenue data used here is four times the quarterly (Dec. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Akers Biosciences ROA % Related Terms

Thank you for viewing the detailed overview of Akers Biosciences's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akers Biosciences (Akers Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.
Executives
Billy Joe White director 191 OTTO ST., PORT TOWNSEND WA 98368
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Christopher C Schreiber director, officer: Exec. Chairman and President AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
John J Gormally director, officer: Chief Executive Officer 80 WALSH DRIVE, MAHWAH NJ 07430
Gary M Rauch officer: VP - Finance, Treasurer 842 ST REGIS COURT, WEST DEPTFORD NJ 08051
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Brandon Thomas Knox director 771 EAGLE ROAD, VILLANOVA PA 19085
Akers Raymond Francis Jr director, officer: Executive Chairman, Secretary 171 E. ESSEX AVE, SEWELL NJ 08080
Thomas J Knox director 1717 ARCH STREET, SUITE 3820, PHILADELPHIA PA 19103
Robert E Andrews director 215 4TH AVENUE, HADDON HEIGHTS NJ 08035

Akers Biosciences (Akers Biosciences) Headlines